Insider Selling: Achillion Pharmaceuticals major shareholder Sells 128,649 Shares of Stock (ACHN)
Achillion Pharmaceuticals (NASDAQ:ACHN) major shareholder Qvt Associates Gp Llc sold 128,649 shares of the company’s stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $7.66, for a total transaction of $985,451.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Several analysts have recently commented on the stock. Analysts at Robert W. Baird upgraded shares of Achillion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday. They now have a $12.00 price target on the stock, up previously from $4.00. Separately, analysts at Deutsche Bank raised their price target on shares of Achillion Pharmaceuticals to $6.00 in a research note on Tuesday. Finally, analysts at JMP Securities upgraded shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday. They now have a $13.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company’s stock. Achillion Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $6.11.
Achillion Pharmaceuticals (NASDAQ:ACHN) traded down 6.32% on Thursday, hitting $6.83. 21,013,960 shares of the company’s stock traded hands. Achillion Pharmaceuticals has a 52 week low of $2.26 and a 52 week high of $8.49. The stock’s 50-day moving average is $3.09 and its 200-day moving average is $3.2. The company’s market cap is $661.1 million.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.16) by $0.01. Analysts expect that Achillion Pharmaceuticals will post $-0.77 EPS for the current fiscal year.
Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.